CHICAGO, June 21, 2011 /PRNewswire-USNewswire/ — According to a
new study released today at the annual meeting of the Drug
Information Association in Chicago, the greater Kansas City region
is home to a significant cluster of contract research organizations
(CROs) and contract service providers (CSPs), with more than $1
billion in annual revenue.
Commissioned through an innovative partnership consisting of the
Kansas Bioscience Authority, the Kansas Bio Organization, the
Kansas City Area Life Sciences Institute and the Kansas City Area
Development Council, the study also found that the Kansas City
region is home to approximately 70 CROs and CSPs employing more
than 9,000 people.
“Working with our regional partners, we commissioned this study
because we knew there was a wealth of contract research and service
activity in the region,” said David Vranicar, interim president and
CEO of the Kansas Bioscience Authority, “but it was surprising
– even to those of us who know the space well – to
learn that this is an industry that exceeds one billion dollars in
revenue locally. Of equal significance is the diversity of the
region’s CRO and contract service provider offerings, spanning
every stage of drug development required to identify and bring new
drugs and devices to market.”
Nearly every major global pharmaceutical company has utilized
contract research services in the Kansas City region.
Increasing pressure on pharmaceutical and biotech companies to
address unmet medical needs is driving demand for CROs and CSPs to
deliver high-quality contract research. Outsourcing these
activities gives drug developers increased flexibility to
accommodate research and staffing constraints in their development
pipelines. By leveraging the specific research experience provided
by CROs and CSPs, outsourcing can significantly lower costs and
shorten timelines.
“Research sponsors need to be confident that CROs and CSPs can
deliver rig
‘/>”/>
